Soleus Capital Management, L.P.
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1802630
GREENWICH, CT
Position in ELVN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$8,408,107
-$641,957 QoQ
Shares Held
165,677
-28.2% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#63
of 210 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Soleus Capital Management, L.P. holds $1,743,217,207 across 63 Biotechnology names. ELVN ranks #40 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KRYS |
Krystal Biotech, Inc.
|
939,254 | $349,092,534 | |
| 2 | CELC |
Celcuity Inc.
|
1,704,318 | $178,305,749 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
2,927,895 | $160,858,551 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
1,843,504 | $72,117,876 | |
| 5 | VCEL |
Vericel Corp
|
1,459,152 | $64,917,672 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
177,517 | $59,430,916 | |
| 7 | GERN |
Geron Corp
|
42,808,659 | $54,795,083 | |
| 8 | ERAS |
Erasca, Inc.
|
2,700,000 | $49,464,000 |
All Filings in ELVN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,408,107 | 165,677 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $9,050,064 | 230,869 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $15,785,000 | 1,025,000 | Shares | Sole | 2026-02-12 | |
| 2024-12-31 | $1,696,612 | 75,405 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $6,122,065 | 239,705 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $17,977,676 | 769,263 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||